Bibliography
- TUTRONE WD, KAGEN MH, BARBAGALLO J, WEINBERG JM: Biologic therapy for psoriasis: a brief history, II. Cutts. (2001) 68(6):367–372.
- Results of the National Psoriasis Foundation 2001 Psoriasis and Psoriatic Arthritis Benchmark Survey. Prepared by Gail Zimmerman, President and CEO National Psoriasis Foundation.
- LOMHOLT G: Psoriasis: prevalence, spontaneous course and genetics: a census study on the prevalence of skin diseases on the Faroe Islands. Copenhagen, Denmark: GEC GAD, 1963.
- HENSELER T, CHRISTOPHERS E: Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J. Am. Acad. DermatoL (1985) 13(3):450–456.
- INTERNATIONAL PSORIASIS GENETICS CONSORTIUM. The International Psoriasis Genetics Study: assessing linkage to 14 candidate susceptibility loci in a cohort of 942 affected sib pairs. Am. J. Hum. Genet. (2003) 73(2):430–437.
- CAPON F, SEMPRINI S, CHIMENTI S et al.: Fine mapping of the PSORS4 psoriasis susceptibility region on chromosome 1q21. J. Invest. Dermatol (2001) 116(5):728–730.
- BOWCOCK AM, COOKSON WO: The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. Hum. Mol. Genet. (2004) 13 Spec No 1:R43–R55.
- •An excellent review of the genetics of psoriasis and psoriatic arthritis.
- FREDRIKSSON T, PETERSSON U: Severe psoriasis — oral therapy with a new retinoid. Dermatologica (1978) 157:238–241.
- FINLAY AY, KHAN GK: Dermatology LifeQuality Index (DLQI): a simple practical measure for routine clinical use. Clin. Exp. Dermatol. (1994) 19:210–216.
- BAKER BS, SWAIN AF, VALDIMARSSON H, FRY L: T-cell subpopulations in the blood and skin of patients with psoriasis. Br. J. Dermatol. (1984) 110:37–44.
- COOPER KD: Skin-infiltrating lymphocytes in normal and disordered skin: activation signals and functional roles in psoriasis and mycosis fungoides-type cutaneous T cell lymphoma. J. Dermatol. (1992) 19:731–737.
- GOTTLIEB AB: Novel immunotherapies for psoriasis: clinical research delivers new hope for patients and scientific advances. J. Invest. Dermatol. Symp. Proc. (2004) 9(1):79–83.
- •A good review of targeted immunotherapy research in psoriasis.
- GUPTA MA, SCHORK NJ, GUPTA AK, KIRKBY S, ELLIS CN: Suicidal ideation in psoriasis. Int. J. Dermatol. (1993) 32(3):188–190.
- RAPP SR, FELDMAN SR, EXUM ML, FLEISCHER AB JR, REBOUSSIN DM: Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol. (1999) 41(3 Pt 1):401–407.
- GISONDI P, GUBINELLI E, COCUROCCIA B, GIROLOMONI G: Targeting tumor necrosis factor-alpha in the therapy of psoriasis. Curr. Drug Targets Inflamm. Allergy. (2004) 3(2):175–183.
- VICTOR FC, GOTTLIEB AB, MENTER A: Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. Clin. Dermatol. (2003) 21(5):392–397.
- VICTOR FC, GOTTLIEB AB: TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis. J. Drugs Dermatol. (2002) 1(3):264–275.
- HUGHES J, RUSTIN M: Corticosteroicis. Clin. Dermatol. (1997) 15: 715–721.
- ASHCROFT DM, PO AL, WILLIAMS HC, GRIFFITHS CE: Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. Br. Med. J. (2000) 320(7240):963–967.
- MICHEL S, JOMARD A, DEMARCHEZ M: Pharmacology of adapalene. Br. J. Dermatol. (1998) 139(Suppl. 52):3–7.
- SCHWARTZ PM, BARNETT SK, ATILLASOY ES, MILSTONE LM: Methotrexate induces differentiation of human keratinocytes. Proc. Natl Acad. Sci. USA (1992) 89(2)594–598.
- CATHER J, MENTER A: Novel therapies for psoriasis. Am. J. Clin. Dermatol. (2002) 3(3):159–173.
- •A good review of biologicals and other therapies for psoriasis.
- ROENIGK HH, AUERBACH R, MAIBACH H, WEINSTEIN G, LEBWOHL M: Methotrexate in psoriasis: consensus conference. J. Am. Acad. Dermatol. (1998) 38:478–485.
- ELLIS CN, GORSULOWSKY DC, HAMILTON TA et al.: Cyclosporine improves psoriasis in a double-blind study. JAMA (1986) 256(22):3110–3116.
- HARPER JI, KEAT AC, STAUGHTON RC: Cyclosporin for psoriasis. Lancet (1984) 2(8409):981–982.
- GRIFFITHS CE, POWLES AV, MCFADDEN J, BAKER BS, VALDIMARSSON H, FRY L: Long-term cyclosporin for psoriasis.Br. j Dermatol. (1989) 120(2):253–260.
- BOS JD, MEINARDI MM, VAN JOOST T, HEULE F, POWLES AV, FRY L: Use of cyclosporin in psoriasis. Lancet (1989) 23–30;2(8678–8679): 1500–1502.
- HEULE F, MEINARDI MM, VAN JOOST T, BOS JD: Low-dose cyclosporine effective in severe psoriasis: a double-blind study. Transplant Proc. (1988) 20(3 Suppl. 4):32–41.
- WENTZELL JM, BAUGHMAN RD, O'CONNOR GT, BERNIER GM JR: Cyclosporine in the treatment of psoriasis. Arch. Dermatol. (1987) 123(2):163–165.
- PICASCIA DD, GARDEN JM, FREINKEL RK, ROENIGK HH JR: Treatment of resistant severe psoriasis with systemic cyclosporine. J. Am. Acad. Dermatol. (1987) 17(3):408–414.
- MEINARDI MM, BOS JD: Cyclosporine maintenance therapy in psoriasis. Transplant Proc. (1988) 20(3 Suppl. 4):42–49.
- FINZI AF, MOZZANICA N, CATTANEO A, CHIAPPINO G, PIGATTO PD: Effectiveness of cyclosporine treatment in severe psoriasis: a clinical and immunologic study. J. Am. Acad. Dermatol. (1989) 21(1):91–97.
- HEYDENDAEL VM, SPULS PI, OPMEER BC et al.: Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl. J. Med. (2003) 349:658–665.
- KOLBACH DN, NIEBOER C: Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment. J. Am. Acad. Dermatol. (1992) 27: 769–771.
- ALTMEYER PJ, MATTHES U, PAWLAK F et al.: Antipsoriatic effect of fumaric acid derivatives. J. Am. Acad. Dermatol. (1994) 30: 977–981.
- MROWIETZ U, CHRISTOPHERS E, ALTMEYER P: Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. Br. J. Dermatol. (1998) 138:456–460.
- NIEBOER C, DE HOOP D, VAN LOENEN AC et al.: Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis. J. Am. Acad. Dermatol. (1989) 20:601–608.
- TREUMER F, ZHU K, GLASER R, MROWIETZ U: Dimethylfumarate is a potent inducer of apoptosis in human T cells. J. Invest. Dermatol. (2003) 121(6):1383–1388.
- GHORESCHI K, ROCKEN M: Immune deviation strategies in the therapy of psoriasis. Curr. Drug Targets Inflamm. Allergy (2004) 3(2):193–198.
- ROODNAT JI, CHRISTIAANS MH, NUGTEREN-HUYING WM et al: Acute kidney insufficiency in patients treated with fumaric acid esters for psoriasis. Ned Hjdschr. Geneeskd. (1989)133:2623–2626.
- KOLBACH DN, NIEBOER C: Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment. J. Am. Acad. Dermatol. (1992) 27: 769–771.
- ALTMEYER P, HARTWIG, R, MATTHES U: Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory of psoriasis vulgaris. A study of 83 patients. Hautarzt. (1996) 47:190–196.
- OZAWA M, FERENCZI K, KIKUCHI T: 312-nanometer ultraviolet B light (Narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J. Exp. Med. (1999) 189(4):711–718.
- •Strong support for apoptosis as the mechanism of action of narrow-band UVB phototherapy.
- JOHNSON R, STAIANO-COICO L, AUSTIN L, CARDINALE I, NABEYA-TSUKIFUJI R, KRUEGER JG: PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in human T-lymphocytes. Photochem. PhotobioL (1996) 63(5):566–571.
- ELLIS CN, KRUEGER GG: Alefacept clinical study group: treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl. J. Med. (2001) 345(4):248–255.
- KRUEGER GG, ELLIS CN: Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br. J. Dermatol (2003) 148(4):784–788.
- KRUEGER GG. Clinical response to alefacept: results of a Phase III study of intravenous administration of alefacept in patients with chronic plaque psoriasis. J. Eur. Acad. Dermatol Venereol (2003) 17(Suppl. 2):17–24.
- CATHER JC, CATHER JC, MENTER A: Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin. Biol. Ther. (2003) 3(2):361–370.
- GOTTLIEB AB, MILLER B, LOWE NJ et al.: Subcutaneously administered efalizumab (anti-CD 11a) improves signs and symptoms of moderate to severe plaque psoriasis. J. Cutan. Med. Surg (2003) Apr 30 (Epub ahead of print).
- LEBWOHL M, TYPING SK, HAMILTON TK et al.: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl. J. Med. (2003) 349 (21) :2004–2013.
- MEASE PJ: Current treatment of psoriatic arthritis. Rheum. Dis. Clin. N Am. (2003) 29:495–511.
- ORY P, SHARP JT, SALONEN D et al: Etanercept (Enbrel®) inhibits radiographic progression in patients with psoriatic arthritis [abstract]. Arthritis Rheum. (2002) 46(Suppl): S196. Abstract 442.
- ORY P, SHARP JT, SALONEN D et al: Etanercept (Enbrel®) inhibits radiographic progression in patients with psoriatic arthritis. Paper presented at: Annual European Congress of Rheumatology; 30 June (2003) Lisbon, Portugal. Abstract 0P0089.
- LEONARDI CL, POWERS JL, MATHESON RT et al.: Etanercept as monotherapy in patients with psoriasis. N Engl. J. Med. (2003) 349 (21) :2014–2022.
- GUENTHER L, VAN DE KERKHOF PC, SNELLMAN E et al.: Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle- controlled clinical trial. Br. J. Dermatol (2002) 147(2):316–323.
- BOWMAN PH, MALONEY JE, KOO JY: Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study./ Am. Acad. Dermatol. (2002) 46(6):907–913.
- KRUEGER JG: The immunologic basis forthe treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol (2002) 46(1):1–23.
- MUELLER W, HERMANN B: Cyclosporin A for psoriasis. N Engl. J. Med. (1979) 301:555.
- BAKER BS, SWAIN AF, FRY L, VALDIMARSSON H: Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br. J. Dermatol (1984) 110:555–564.
- GOTTLIEB SL, GILLEAUDEAU P, JOHNSON R et al.: Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. (1995) 1(5):442–447.
- VISSERS WH, ARNDTZ CH, MUYS L, VAN ERP PE, DE JONG EM, VAN DE KERKHOF PC: Memory effector (CD45R0*) and cytotoxic (CD8*) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br. J. Dermatol (2004) 150(5):852–859.
- BONIFATI C, CARDUCCI M, CORDIALI FEI P et al.: Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients-relationships with disease severity. Clin. Exp. Dermatol. (1994) 19(5):383–387.
- ETTEHADI P, GREAVES MW, WALLACH D, ADERKA D, CAMP RD: Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin. Exp. Immunol (1994) 96(1):146–151.
- •Gives clear support for the role of TNF-a in the pathogenesis of psoriasis.
- PARTSCH G, STEINER G, LEEB BF et al: Highly increased levels of tumor necrosis factor-a and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J. Rheumatol (1997) 24:518–523.
- RITCHLIN C, HAAS-SMITH SA, HICKS D et al: Patterns of cytokine production in psoriatic synovium. Rheumatol (1998) 25:1544–1552.
- DANNING CL, ILLEI GG, HITCHON C et al.: Macrophage-derived cytokine and nuclear factor B p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum. (2000) 43:1244–1256.
- GOTTLIEB AB, BOS JD: Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin. Immunol (2002) 105(2):105–116.
- •A review of biological therapy in psoriasis.
- CHEN DM, GORDON K, LEONARDI C, MENTER MA: Adalimumab efficacy and safety in patients with moderate to severe chronic plaque psoriasis: preliminary findings from a 12-week dose-ranging trial. Poster presented at: American Academy of Dermatology 62nd Annual Meeting; February 9, 2004; Washington, DC. Abstract 2.
- GOTTLIEB AB, MASUD S, RAMAMURTHI R et al.: Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J. Am. Acad. Dermatol. (2003) 48(1):68–75.
- OH CJ, DAS KM, GOTTLIEB AB: Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J. Am. Acad. Dermatol (2000) 42(5 Pt 1):829–830.
- CHAUDHARI U, ROMANO P, MULCAHY LD, DOOLEY LT, BAKER DG, GOTTLIEB AB: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet (2001) 9;357(9271):1842–1847.
- ••Landmark trial that demonstrates theefficacy and safety of infliximab in psoriasis.
- GOTTLIEB AB, CHAUDHARI U, MULCAHY LD, LI S, DOOLEY LT, BAKER DG: Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J. Am. Acad. Dermatol. (2003) 48(6):829–835.
- ANTONI CE, KAVANAUGH A, KIRKHAM B et al.: The infliximab multinational psoriatic arthritis controlled trial (IMPACT): substantial efficacy on synovitis and psoriatic arthritis with or without concomitant DMARD therapy. Program and abstracts of the Annual European Congress of Rheumatology (EULAR 2003); June 18–21, 2003; Lisbon, Portugal. Abstract 0P0082.
- Ninth International Psoriasis Symposium; June 18–22, 2003; New York, NY
- GHORESCHI K, THOMAS P, BREIT S et al.: Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. (2003) 9(1):40–46.
- GHORESCHI K, MROWIETZ U, ROCKEN M: A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses. J. Mol Med. (2003) 81(8):471–480.
- ASADULLAH K, DOCKE WD, EBELING M et al.: Interleukin 10 treatment of psoriasis: clinical results of a Phase II trial. Arch. Dermatol. 1999 Feb; 135(2):187–192.
- ASADULLAH K, STERRY W, STEPHANEK K et al: IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. Clin. Invest. (1998) 101(4):783–794.
- TREPICCHIO WL, OZAWA M, WALTERS TB et al: Interleukin-11 therapy selectively downregulates Type I cytokine proinflammatory pathways in psoriasis lesions. J. Clin. Invest. (1999) 1040 0:1527–1537.
- KRUEGER GG, BELL GM, HUANG S, et al: ABX-1L8 in the treatment of psoriasis: clinical results. Society for Investigative Dermatology Annual Meeting, May 2002. Poster presentation.
- YAWALKAR N, KARLEN S, HUNGER R, BRAND CU, BRAATHEN LR: Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol (1998) 111(6):1053–1057.
- KAUFFMAN CL, ARIA N, TOICHI E et al.: A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J. Invest. Dermatol (Epub ahead of print)
- GOTTLIEB AB, LEBWOHL M, SHIRIN S et al.: Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose placebo-controlled study./ Am. Acad. Dermatol. (2000) 43:595–604.
- SKOV L, KRAGBALLE K, ZACHARIAE C et al: HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. Arch. Dermatol 2003 Nov; 139(11):1433–1439.
- GOTTLIEB AB, LEBWOHL M, TOTORITIS MC et al.: Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody. J. Am. Acad. Dermatol (2002) 47(5):692–700.
- GOTTLIEB AB, KANG S, LINDEN KG et al.: Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin. Immunol (2004) 111(1):28–37.
- KRUEGER JG, WALTERS TB, MIYAZAWA M et al.: Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J..Am. Acad. Dermatol. (2000) 43(3):448–458.
- TRAJKOVIC V: Nuvion. Protein Design Labs. Curr. Opin. Investig. Drugs (2002) 3:411–414.
- LANGLEY R, ROENIGK H, DINGI VAN C: Safety, tolerance, and disease activity of MEDI-507 for the treatment of moderate to severe psoriasis: a review of Phase I results. In: 2nd Joint Meeting International Psoriasis Symposium and European Congress on Psoriasis. 19–24 June, (2001) Plenary 7.
- LIU V MACKOOL BT: Mycophenolate indermatology. J. Dermatolog. Treat. (2003) 14(4):203–211.
- GEILEN CC, ARNOLD M, ORFANOS CE: Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients. Br. J. Dermatol (2001) 144(3):583–586.
- SCHRADER P, MOOSER G, PETER RU, PUHL W: [Preliminary results in the therapy of psoriatic arthritis with mycophenolate mofetil] Z. RheumatoL (2002) 61(5):545–550.
- RAPPERSBERGER K, KOMAR M, EBELIN ME et al.: Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J. Invest. Dermatol (2002) 119(4):876–887.
- WOLFF K, STUETZ A: Pimecrolimus forthe treatment of inflammatory skin disease. Expert Opin. Pharmacother. (2004) 5(3):643–655.
- EUROPEAN FK 506 MULTICENTRE PSORIASIS STUDY GROUP: Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch. Dermatol. (1996) 132: 419–423.
- ZONNEVELD IM, RUBINS A, JABLONSKA S et al.: Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch. Dermatol. (1998) 134(9):1101–1102.
- FREEMAN AK, LINOWSKI GJ, BRADY C et al.: Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J. Am. Acad. Dermatol. (2003) 48(4):564–568.
- REMITZ A, REITAMO S, ERKKO P, GRANLUND H, LAUERMA Al: Tacrolimus ointment improves psoriasis in a microplaque assay. Br. J. Dermatol (1999) 141(1):103–107.
- FIORENTINO DF, VOSGANIAN, LEVIN C, KIMBALL AB: A double-blind placebo-controlled randomized parallel dose comparison of topically applied cyclosporine A conjugate (CGC1072) versus vehicle control in psoriasis patients. Program of the 61st Annual Meeting of the American Academy of Dermatology. 22–26 March (2003) San Francisco, California. Poster 590.
- ELLIS CN, VARANI J, FISHER GJ et al: Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch. Dermatol. (2000) 136(5):609–616.
- BHAGAVATHULA N, NERUSU KC, LAL A et al: Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes. J. Invest. Dermatol. (2004) 122(1):130–139.
- WALKER PS, GOTTLIEB A, GUENTHER L, et al: Oral tazarotene (4.5 mg capsule) in patients with moderate to very severe plaque psoriasis. Poster presented at: American Academy of Dermatology Academy 2003. 25–29 July (2003) Chicago, IL.
- SMIT JV, FRANSSEN ME, DE JONG EM et al: A Phase II multicenter clinical trial of systemic bexarotene in psoriasis. J. Am. Acad. DermatoL (2004) 51(2):249–256.
- SMIT JV, DE JONG EM, VAN HOOIJDONK CA, OTERO ME, BOEZEMAN JB, VAN DE KERKHOF PC: Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin. J. Am. Acad. DermatoL (2004) 51(2):257–264.
- LEBWOHL M: Advances in psoriasis therapy. DermatoL Clin. (2000)18:13–19.
- TIWARI SB, KUMAR BCR, UDUPA N, BALACHANDRAN C: Topical methotrexate delivered by iontophoresis in the treatment of recalcitrant psoriasis — a case report. Int. J. DermatoL (2003) 42(2):157–159.
- KUMAR RBC, INDERJEET K, BHUSHAN K: Topical methotrexate therapy in palmoplantar psoriasis. Indian J. DermatoL Venereolo. Leprolo. (1999) 65(6):270–272.
- MORROW T: The 'heartbreak of psoriasis' has met its match! Manag Care. (2003) 12(6): 13,17–18.
Websites
- http://www.aad.org/pamphlets/ Psoriasis.html. Accessed October 2004. American Academy of Dermatology website — Psoriasis Pr(1994).
- http://www.syntapharma.com/products/ immune.phpSTA5326. Accessed October 2004. Synta Pharmaceuticals Corp. 5TA5326.
- http://www.pdl.com/applications/ press_releases.cfm?newsId=36. Accessed November 2004. Protein Design Labs — Press Releases.
- http://www.pvct.com/pharmatech.html. Accessed October 2004. Pharmatech — Provectus Pharmaceuticals, Inc.